Monitoring of fibrin generation during thrombolytic therapy of acute myocardial infarction with recombinant tissue-type plasminogen activator.

Fibrinopeptide A (FPA) is a very sensitive marker of fibrin generation in vivo. Because an imbalance between thrombogenic and thrombolytic forces may be responsible for the failure to recanalize and for reocclusion of coronary arteries, such a marker could be of eminent value during thrombolytic treatment of acute myocardial infarction. Thirty-four consecutive patients with acute myocardial infarction (peak creatine kinase level, 1,869 +/- 1,543 IU/l) were treated with 100 mg recombinant tissue-type plasminogen activator (rt-PA) 3.1 +/- 1.1 hours after onset of chest pain. Angiography 12.5 +/- 6.1 days later revealed an 81% patency rate of the infarct-related vessel. FPA plasma levels (normal, 1.9 +/- 0.5 ng/ml) were 34 +/- 46 ng/ml on admission and 93 +/- 86 ng/ml (538 +/- 674% with respect to each patient's admission level) after 90 minutes of rt-PA infusion (p less than 0.01). In patients without evidence of reocclusion (including three primary failures), FPA levels fell under continuous heparin infusion to 6.7 +/- 9.7 ng/ml (24 +/- 33%, p less than 0.01) within 30 minutes and were 3.1 +/- 2.2 ng/ml (15 +/- 15%, p less than 0.01), 1.6 +/- 1.1 ng/ml (8 +/- 10%, p less than 0.01), and 2.5 +/- 3.0 ng/ml (12 +/- 16%, p less than 0.01) 30 minutes, 9 hours, and 21 hours, respectively, after completion of rt-PA therapy. Five patients sustained intermittent or permanent coronary reocclusion after primary thrombolytic success. Their early postlytic FPA levels (13-51 ng/ml) remained high or increased again despite adequate anticoagulation. FPA allows the monitoring of fibrin generation during acute myocardial infarction and thrombolytic therapy. Despite successful recanalization, fibrin generation is increased under rt-PA administration before anticoagulation. Patients under anticoagulation with postlytic FPA levels less than 5 ng/ml or below their admission value seem to be at low risk of reocclusion for several days. FPA levels that are persistently high or that increase again despite adequate anticoagulation indicate ongoing fibrin generation. However, whether FPA can indeed be considered a useful marker of reocclusion remains to be confirmed in a larger population of patients with acute myocardial infarction.

[1]  M. Levine,et al.  Human tissue-type plasminogen activator releases fibrinopeptides A and B from fibrinogen. , 1988, The Journal of clinical investigation.

[2]  K. Friedman,et al.  Thrombolytic therapy with tissue plasminogen activator or streptokinase induces transient thrombin activity. , 1988, Blood.

[3]  P. Lichtlen,et al.  THROMBIN/ANTITHROMBIN-III COMPLEX LEVEL AS EARLY PREDICTOR OF REOCCLUSION AFTER SUCCESSFUL THROMBOLYSIS , 1988, The Lancet.

[4]  J. Willerson,et al.  Mediation of reocclusion by thromboxane A2 and serotonin after thrombolysis with tissue-type plasminogen activator in a canine preparation of coronary thrombosis. , 1988, Circulation.

[5]  G. FitzGerald,et al.  Marked platelet activation in vivo after intravenous streptokinase in patients with acute myocardial infarction. , 1988, Circulation.

[6]  A. Jaffe,et al.  Paradoxic elevation of fibrinopeptide A after streptokinase: evidence for continued thrombosis despite intense fibrinolysis. , 1987, Journal of the American College of Cardiology.

[7]  A. Ross,et al.  Reinfarction, recurrent angina, and reocclusion after thrombolytic therapy. , 1987, Circulation.

[8]  W. Steinbrunn,et al.  Does exercise-induced myocardial ischaemia cause enhanced platelet activation and fibrin formation in patients with stable angina and severe coronary artery disease? , 1987, European heart journal.

[9]  J. Gore,et al.  Peak creatine kinase as a measure of effectiveness of thrombolytic therapy in acute myocardial infarction. , 1987, The American journal of cardiology.

[10]  C. Francis,et al.  INCREASED PLASMA CONCENTRATION OF CROSSLINKED FIBRIN POLYMERS IN ACUTE MYOCARDIAL INFARCTION , 1987, Thrombosis and Haemostasis.

[11]  J. Conard,et al.  Theoretic and Practical Considerations on Laboratory Monitoring of Thrombolytic Therapy , 1987, Seminars in thrombosis and hemostasis.

[12]  J. Soria,et al.  Specific determination and identification of cross-linked fibrin degradation products in patients under thrombolytic therapy for myocardial infarction. , 1987, Seminars in thrombosis and hemostasis.

[13]  E. Topol,et al.  Prediction of infarct coronary artery recanalization after intravenous thrombolytic therapy. , 1987, The American journal of cardiology.

[14]  P. Théroux,et al.  Fibrinopeptide A and platelet factor levels in unstable angina pectoris. , 1987, Circulation.

[15]  C. Francis,et al.  Assessment of fibrin degradation products during fibrinolytic therapy for acute myocardial infarction. , 1986, Circulation.

[16]  A. Gallino,et al.  Fibrin formation and platelet aggregation in patients with acute myocardial infarction: effects of intravenous and subcutaneous low-dose heparin. , 1986, American heart journal.

[17]  A. Jaffe,et al.  Importance of continued activation of thrombin reflected by fibrinopeptide A to the efficacy of thrombolysis. , 1986, Journal of the American College of Cardiology.

[18]  F V Lucas,et al.  Pharmacodynamics of tissue-type plasminogen activator characterized by computer-assisted simulation. , 1986, Circulation.

[19]  I. Palacios,et al.  Acute coronary reocclusion after thrombolysis with recombinant human tissue-type plasminogen activator: prevention by a maintenance infusion. , 1986, Circulation.

[20]  E. Braunwald,et al.  Intravenous recombinant tissue-type plasminogen activator in patients with acute myocardial infarction: a report from the NHLBI thrombolysis in myocardial infarction trial. , 1986, Circulation.

[21]  D. Collen,et al.  Pharmacokinetics and systemic fibrinogenolytic effects of recombinant human tissue-type plasminogen activator (rt-PA) in humans. , 1985, The Journal of pharmacology and experimental therapeutics.

[22]  Paul,et al.  Characterization of the kinetic pathway for liberation of fibrinopeptides during assembly of fibrin. , 1985, The Journal of biological chemistry.

[23]  A. Gallino,et al.  Fibrin formation and platelet aggregation in patients with severe coronary artery disease: relationship with the degree of myocardial ischemia. , 1985, Circulation.

[24]  A. Jaffe,et al.  Fibrinopeptide A: a marker of acute coronary thrombosis. , 1985, Circulation.

[25]  R. W. Brower,et al.  RANDOMISED TRIAL OF INTRAVENOUS RECOMBINANT TISSUE-TYPE PLASMINOGEN ACTIVATOR VERSUS INTRAVENOUS STREPTOKINASE IN ACUTE MYOCARDIAL INFARCTION Report from the European Cooperative Study Group for Recombinant Tissue-type Plasminogen Activator , 1985, The Lancet.

[26]  H. S. Mueller,et al.  The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. , 1985, The New England journal of medicine.

[27]  D. Hoppensteadt,et al.  Performance Characteristics of a Simple Radioimmunoassay for Fibrinopeptide A , 1984, Seminars in thrombosis and hemostasis.

[28]  A. Haeberli,et al.  Effect of heparin on plasma fibrinopeptide A in patients with acute myocardial infarction. , 1984, Circulation.

[29]  R. Bertina,et al.  Fibrinopeptide A and beta thromboglobulin in patients with angina pectoris and acute myocardial infarction. , 1984, American heart journal.

[30]  C. Francis,et al.  Thrombin activity of fibrin thrombi and soluble plasmic derivatives. , 1983, The Journal of laboratory and clinical medicine.

[31]  L. Johnson,et al.  Exercise-induced myocardial ischemia in patients with coronary artery disease: lack of evidence for platelet activation or fibrin formation in peripheral venous blood. , 1983, Journal of the American College of Cardiology.

[32]  J. Hermans,et al.  Diagnostic value of fibrinopeptide A and beta-thromboglobulin in acute deep venous thrombosis and pulmonary embolism. , 2009, Acta medica Scandinavica.

[33]  P. Cannon,et al.  Fibrinopeptide A, platelet factor 4, and beta-thromboglobulin levels in coronary heart disease. , 1982, Blood.

[34]  C. Prowse,et al.  Proteolysis of fibrinogen in healthy volunteers following major and minor vivo plasminogen activation. , 1982, Thrombosis research.

[35]  R. Asinger,et al.  Incidence of left-ventricular thrombosis after acute transmural myocardial infarction. Serial evaluation by two-dimensional echocardiography. , 1981, The New England journal of medicine.

[36]  R. Abbate,et al.  Increased fibrinopeptide A formation and thromboxane A2 production in patients with ischemic heart disease: relationships to coronary pathoanatomy, risk factors, and clinical manifestations. , 1981, American heart journal.

[37]  C. Kockum Radioimmunoassay of fibrinopeptide A - immunoreactivity of fibrinogen and fibrinogen fragments. , 1980, Thrombosis research.

[38]  J. V. van Mourik,et al.  Effect of anticoagulant treatment measured by fibrinopeptide A (fpA) in patients with venous thrombo-embolism. , 1980, Thrombosis research.

[39]  H. Johnsson,et al.  Fibrinopeptide a (FPA) in patients with acute myocardial infarction. , 1979, Thrombosis research.

[40]  E. Shaw,et al.  D-Phe-Pro-ArgCH2C1-A selective affinity label for thrombin. , 1979, Thrombosis research.

[41]  J. Hirsh,et al.  Plasma fibrinopeptide A levels in symptomatic venous thromboembolism. , 1978, Blood.

[42]  P. Straub,et al.  A radioimmunoassay technique for the rapid measurement of human fibrinopeptide A. , 1977, Thrombosis research.

[43]  J. van der Meer,et al.  Fibrinopeptide a Determination in Clinical Plasma Samples , 1977, Thrombosis and Haemostasis.

[44]  H. L. Nossel Radioimmunoassay of fibrinopeptides in relation to intravascular coagulation and thrombosis. , 1976, The New England journal of medicine.

[45]  R. Canfield,et al.  Specificity of Antisera to Human Fibrinopeptide A Used in Clinical Fibrinopeptide A Assays , 1976, Thrombosis and Haemostasis.

[46]  C. Kockum Radioimmunoassay of fibrinopeptide A-clinical applications. , 1976, Thrombosis research.

[47]  R. Canfield,et al.  Measurement of fibrinopeptide A in human blood. , 1974, The Journal of clinical investigation.

[48]  J. Shillingford,et al.  Frequency of venous thrombosis after myocardial infarction. , 1971, Lancet.

[49]  A. Clauss,et al.  Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens , 1957 .

[50]  F. R. Bettelheim The clotting of fibrinogen. II. Fractionation of peptide material liberated. , 1956, Biochimica et biophysica acta.